ELV — Elevance Health Inc. stock price, charts and financials

QT66Elevance Health Inc.

Elevance Health Inc. (NYSE: ELV) is a Healthcare company in the Medical - Healthcare Plans industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
382.77
+6.93+1.84%
OverviewShort InterestFilings
ELVQT66Elevance Health Inc.·NYSE
382.77+1.84%
TA
Loading chart...
Screen all →
CI+1.08%$282.06CVS+0.90%$105.37HUM+2.93%$374.51CNC+2.48%$63.76UNH+0.23%$415.36MOH-0.43%$194.77OSCR-1.54%$30.74ALHC-1.95%$14.56
Snapshot
IndexS&P 500P/E16.70EPS (ttm)22.50Insider Own0.36%Shs Outstand216.87MPerf Week-0.49%
Market Cap81.51BForward P/E12.71EPS next Y29.58Insider Trans0.19%Shs Float216.41MPerf Month-9.70%
Enterprise Value102.32BPEG-EPS next Q4.73Inst Own-Short Float2.78%Perf Quarter-0.15%
Income4.94BP/S0.41EPS this Y20.58%Inst Trans-Short Ratio3.43Perf Half Y8.32%
Sales201.10BP/B1.82EPS next Y9.03%ROA3.93%Short Interest6.03MPerf YTD7.21%
Book/sh-P/C10.97EPS next 5Y15.26%ROE11.24%52W High444.31 -13.85%Perf Year28.03%
Cash/sh-P/FCF12.96EPS past 3/5Y1.14% 6.92%ROIC7.22%52W Low278.76 37.31%Perf 3Y-19.96%
Dividend Est.6.88 (1.80%)EV/EBITDA12.78Sales past 3/5Y8.34% 10.32%Gross Margin38.95%Volatility3.16% 3.13%Perf 5Y-1.69%
Dividend TTM6.86 (1.79%)EV/Sales0.51EPS Y/Y TTM-12.38%Oper. Margin3.51%ATR (14)13.22Perf 10Y170.39%
Dividend Ex-DateSep 10, 2026Quick Ratio1.52Sales Y/Y TTM13.75%Profit Margin2.47%RSI (14)42.09Recom2.29
Dividend Gr. 3/5Y10.14% 12.47%Current Ratio1.52EPS Q/Q-15.72%SMA20-4.63%Beta0.68Target Price440.17
Payout30.36%Debt/Eq0.69Sales Q/Q1.40%SMA50-5.24%Rel Volume0.59Prev Close375.84
Employees97,100LT Debt/Eq0.72EarningsOct 21SMA2007.03%Avg Volume1.65MPrice382.77
IPO DateOct 30, 2001Option/ShortYes / YesEPS/Sales Surpr.19.94% 1.94%Net Debt/EBITDA2.60Volume976,404Change1.84%
Analyst Ratings
DateActionAnalystRatingTarget
Jul-17-26ReiteratedLeerink PartnersMarket Perform$364 → $395
Jul-16-26ReiteratedBernsteinOutperform$482 → $488
Jul-16-26ReiteratedNew Street$482
Jul-16-26ReiteratedGoldman SachsBuy$370 → $395
Jul-16-26ReiteratedRobert W. Baird$331 → $393
Jul-16-26ReiteratedRBC CapitalSector Perform$439 → $424
Jul-16-26ReiteratedWells FargoOverweight$492 → $473
Jul-16-26ReiteratedBarclaysOverweight$480 → $457
Jul-16-26ReiteratedGuggenheimBuy$399 → $455
Jul-14-26ReiteratedTruist SecuritiesBuy$450 → $475
Latest News
Jul-30-26
Jul-30-2612:00PM
Elevance Health Strengthens Connected Cancer Care Model to Support Consumers Through Their Health Journeybusinesswire.com
Jul-29-26
Jul-29-2602:02PM
Oakmark U.S. Large Value Strategy Q2 2026 Portfolio Reviewseekingalpha.com
03:47AM
Elevance Health, Inc. $ELV Shares Acquired by Amundidefenseworld.net
Jul-28-26
Jul-28-2604:54PM
Elevance Health Has Upside, But Not Yet A BuySeekingAlpha
08:49AM
Stock Market Live July 28, 2028: S&P 500 (SPY) Struggling to Stay Green247wallst.com
Jul-25-26
Jul-25-2611:30AM
Billionaire Investor Seth Klarman's Top 5 Stocks: Would He Buy More Today?247wallst.com
Jul-24-26
Jul-24-2605:08AM
Bessemer Group Inc. Has $1.26 Million Holdings in Elevance Health, Inc. $ELVdefenseworld.net
Jul-23-26
Jul-23-2602:29AM
Elevance Health, Inc. (NYSE:ELV) Given Consensus Rating of “Moderate Buy” by Brokeragesdefenseworld.net
Jul-22-26
Jul-22-2603:55AM
Acumen Wealth Advisors LLC Has $2.03 Million Stock Holdings in Elevance Health, Inc. $ELVdefenseworld.net
Jul-21-26
Jul-21-2609:26PM
The Hidden Engine Behind Elevance Health Stock's Next ClimbYahoo
11:25AM
Artisan Value Fund Q2 2026 Portfolio Updateseekingalpha.com
Jul-20-26
Jul-20-2608:53AM
Elevance Health Chairman Ramiro Peru Buys $336,000 of Shares. What Does This Mean for Investors Right Now?fool.com
Jul-18-26
Jul-18-2604:46AM
Elevance Health Q2 Earnings Call Highlightsdefenseworld.net
Jul-17-26
Jul-17-2603:35PM
Elevance Health CEO Boudreaux Buys $1 Million in Shares. What Does This Mean For its 2026 Outlook?fool.com
Jul-16-26
Jul-16-2606:25PM
Big Hospital Systems Are Dropping Medicare Advantage Plans Mid-Contract. Patients Find Out by Letter247wallst.com
Company

Operating as a major health benefits organization, Elevance Health Inc. commits to guiding consumers, families, and communities across their entire health and wellness path. It facilitates access to vital care, assistance, and tools designed to enable healthier living for approximately 118 million individuals. The company's comprehensive offerings span medical, digital, pharmaceutical, behavioral health, clinical, and other care solutions. Founded in 1944 and based in Indianapolis, Indiana, this entity adopted its current name, Elevance Health Inc., in June 2022, having previously operated as Anthem, Inc.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue201,113199,125176,810171,340156,595138,639121,867104,21392,105
Cost of Goods Sold Incl. D&A122,775148,223127,567124,330116,642102,64588,04581,78671,895
Gross Profit78,33850,90249,24347,01039,95335,99433,82222,42720,210
Selling, General and Administrative Excl. Other
6,33000000000
Research and Development
000000000
Other Operating Expense64,94642,79040,35538,26531,50227,04826,11115,69414,373
Operating Income7,0628,1128,8888,7458,4518,9467,7116,7335,837
Interest Expense1,1301,4021,1851,030851798784746753
Unusual Expense
—————————
Non-Operating Income (Expense)-70020100-223-689-2-16
Net Income Before Taxes5,8626,7107,9047,7157,6007,9256,2385,9855,068
Income Taxes9151,0491,9331,7241,7121,8301,6661,1781,318
Consolidated Net Income4,9635,6625,9805,9875,8946,1044,5724,8073,750
Net Income From Continuing Operations4,9475,6615,9715,9915,8886,0954,5724,8073,750
Net Income4,9635,6625,9805,9875,8946,1044,5724,8073,750
EPS (Recurring)22.5025.1825.8125.3824.5625.2518.2318.8114.53
EPS (Basic, Before Extraordinaries)22.5025.1825.8125.3824.5625.2518.2318.8114.53
EPS (Diluted)22.5025.1225.6825.2224.2824.7317.9818.4714.19
EBITDA8,0079,65810,48210,49010,12610,0258,1767,8646,953
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio17.0113.9614.3718.7021.1318.7417.8616.3518.51
Price To Sales Ratio0.410.390.490.640.790.820.660.740.72
Gross Margin38.9525.5627.8527.4425.5125.9627.7521.5221.94
Operating Margin3.514.075.035.105.406.456.336.466.34
Net Margin2.472.843.383.493.764.403.754.614.07
Shares Outstanding218222233233240244251256254
Market Capitalization83,44477,82285,954109,873123,113113,10480,59477,32066,708
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$449.61$400.17$350.73$301.28$251.84● Close Price0.00M0.34M0.68M1.03M1.37MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
BOUDREAUX GAILPresident and CEOJul 17 '26Buy367.792,7251,002,230171,976Jul 17
PERU RAMIRO GDirectorJul 17 '26Buy366.051,000366,05010,908Jul 17
Penczek Ronald WCAO & ControllerJun 12 '26Sale403.16369148,7663,740Jun 15
Dixon Robert L JRDirectorJun 11 '26Sale401.7715160,66710,734Jun 12
Penczek Ronald WCAO & ControllerMay 19 '26Option Exercise294.301,531450,5795,640May 20
Penczek Ronald WCAO & ControllerMay 19 '26Sale403.131,531617,1924,109May 20
SCHULMAN AMY WDirectorMar 12 '26Sale287.50267,475218Mar 23
Kendrick Charles Morgan JREVP & President, CommercialMar 06 '26Sale284.923,196910,60411,791Mar 09
COLLIS STEVEN HDirectorMar 05 '26Buy289.843,000869,5203,639Mar 06
DeVore Susan D.DirectorAug 19 '25Buy312.151,200374,5803,502Aug 21
BOUDREAUX GAILPresident and CEOJul 18 '25Buy286.948,5002,438,951151,020Jul 18
Kaye MarkEVP & CFOApr 24 '25Sale424.824,5881,949,07418,977Apr 25
Penczek Ronald WCAO & ControllerMar 10 '25Sale415.13443183,9031,847Mar 11
Kendrick Charles Morgan JREVP & President, CommercialMar 05 '25Sale396.303,5041,388,63510,116Mar 05
Kendrick Charles Morgan JREVP & President, CommercialOct 18 '24Sale432.147,4173,205,1828,423Oct 18
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.